Clinical Trial Update: An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Open-label Phase 1 trial evaluating INV-1120 as a single agent and in combination with pembrolizumab in adults with advanced solid tumors; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• INV-1120
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. | Conditions: Cancer, Solid Tumor, Adult | Phase 1 | Status: RECRUITING